Summary Acceleration of secondary tumour growth and metastases following excision of a primary tumour has been attributed to the consequent removal of primary tumour-generated inhibitory factors. However, our studies have shown that surgical wounding of normal tissues significantly stimulated the growth of malignant tissues without the concomitant presence or excision of a tumour mass. A humoral stimulating component was indicated by the proliferative response of tumours and metastases distant from the surgical wound. All 16 human and murine tumours, of nine different histologies, showed a measurable acceleration of growth when implanted in surgically treated animals, suggesting that the ability of malignant tissue to respond to surgical wounding of normal tissue was not histologically or species specific. The proliferative surge of malignant tissues was detectable soon after wounding and had a duration of 2-3 days. The surgical wound as the source of the tumour-stimulating factor(s) was affirmed by the significant inhibition of tumour proliferative responses when a somatostatin analogue was applied topically to the surgical wound within 1 h of wounding, and/or during the critical tumour-stimulatory period of 1-2 days after wounding. A potential therapeutic window for reducing a risk factor that may be inadvertently imposed upon every surgical/oncology patient is indicated.
Inhibition of tumour growth by tumour mass is a phenomenon recognized and repeatedly studied since the early 1900s (Ehrlich, 1908; Marie and Clunet, 1910; Tyzzer, 1913) . Numerous reports, summarized more recently by Keller (1983) and O'Reilly et al (1994) , have indicated that the presence of a primary tumour inhibits the growth rate of metastases or of a second tumour implant, and that removal or eradication of the primary tumour accelerates growth at secondary sites. Early explanations for apparent exacerbations of disease reflected Ehrlich's hypothesis of 'Athrepsia'; that any actively growing tumour removed certain specific nutritive material necessary for growth from the host animal (Ehrlich and Apolant, 1905) . Subsequent explanations stressed surgical relief from growth-limiting factors, such as anatomical boundaries, anoxia and nutritional deficiencies, or that the immunological relation between host and tumour was somehow altered by surgery, thereby facilitating tumour escape. However, the underlying cause of the occasional explosive metastatic manifestation after resection of 'primary' malignancy remained in question. An alternative explanation, proposed by Keller (1983) , suggested that soluble factors released by a tumour suppress the growth of tumours in other sites. Once the primary tumour is removed, its inhibitory influence is likewise abolished, permitting the unchecked growth of metastatic cells. More recently, O'Reilly et al (1994) demonstrated that inhibition of metastases by a primary tumour was mediated, in part, by a circulating angiogenesis inhibitor (angiostatin). They postulated that a primary tumour, while capable of stimulating angiogenesis in its own vascular bed by generating angiogenic stimulators in excess of angiogenesis inhibitors, the angiogenesis inhibitor, by virtue of its longer halflife in the circulation, reaches the vascular bed of a secondary tumour in excess of angiogenic stimulator escaping from the primary tumour or generated by the secondary tumour. While there is little question that, under the conditions hypothesized, excision of the primary tumour would abrogate the tumour-inhibitory effect, the role of the surgical wound, per se, in the phenomenon of accelerated growth of residual tumours and metastases following surgical extirpation or debulking of a primary tumour mass has been obscured by the interpretation that the proliferative response was the consequence of eliminating primary tumour-generated inhibitory factors.
There is now considerable evidence indicating that the overall process of healing and repair of surgically damaged tissue, including the necessary intercellular communication, is highly regulated in humans and other animals by a number of specific, soluble growth factors which are released within the wound environment and which appear to induce neovascularization, leucocyte chemotaxis, fibroblast proliferation, migration and deposition of collagen and other extracellular matrix molecules within the wounds. The growth factors that have been identified and isolated are, typically, specialized soluble proteins or polypeptides (McGrath, 1990; Ksander, 1989; Amento and Beck, 1991; Mustoe et al, 1987; Lynch et al, 1989; Bennett and Schultz, 1993) . Thus, evidence of growth factors released at the site of trauma is extensive. With a more complex description of the various growth factors, it is increasingly apparent that the same mediators of cell growth and stromal synthesis are involved in malignancy, fetal growth and wound healing. In our own studies, surgical traumatization (wounding) of normal connective tissues, such as excision of a segment of skin or abrasion of subcutaneous fascia, induced a significant proliferative response of human prostate tumour xenografts implanted in athymic nude mice (Bogden et al, 1996) . Application of a somatostatin analogue, a neuroendocrine antisecretagogue, to the wound had an inhibitory effect on the proliferative response, suggesting the surgical wound as a source of tumour-stimulatory factors. Our primary objective has been to document further the role of the surgical wound, and thus to differentiate two phenomena: one that focuses on the surgical wounding of normal tissues and the resultant release of tumour-stimulating factors from the wound and the other as defined by O'Reilley et al (1994) , which focuses on the surgical extirpation of a tumour mass and the coincident elimination of tumour-generated inhibitory factors. The feasibility of inducing a therapeutic antiproliferative effect by treating the surgical wound with a somatostatin analogue is demonstrated. Lanreotide (LAN) treatment Lanreotide (BIM-23014C, Somatuline) having the structure [D-j3-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2] acetate is a long-acting octapeptide analogue of somatostatin (SRIF), a neuroendocrine antisecretagogue (Heiman et al, 1987 (Table 2) . One hundred athymic nude females were randomized into ten groups of ten animals per group. Groups 1 to 5 were surgically traumatized in the morning of day 0 by the sterile excision of a full-thickness skin segment from the left flank. Groups IC to 5C were not surgically treated to serve as non-traumatized controls. Groups IC and 1 were implanted with 105 B16-F10 melanoma cells s.c. in the right flank in the afternoon of day 0, i.e. 4-6 h after wounding of group 1. Subsequently, groups 2C and 2 were implanted on day 1, groups 3C and 3 on day 2, groups 4C and 4 on day 3 and groups 5C and 5 on day 4 after wounding. Thus, the surgically traumatized groups were paired with non-traumatized controls as shown in Table 2 . No other treatment was administered. Although the experimental design required five tumour cell donor animals during the five consecutive implantation days, traumatized groups and their non-traumatized controls were each implanted with tumour cells from the same donor. The assay was terminated by euthanasia of traumatized and control groups at 14-and 15-day intervals after tumour implantation. Each day of sacrifice was identical for both the traumatized group and its corresponding nontraumatized control group. Vernier caliper measurements of the resultant s.c. tumours were made and tumour weights calculated. Since the duration of the proliferative stimulus was the variable being determined, the inoculum size (cell number) was maintained as a constant.
MATERIAL AND METHODS Animals
Seeding of blood-borne metastases to the lung The effect of surgical trauma and LAN treatment on the seeding and growth of blood-borne metastases to the lung was determined in C57BL/6 female mice implanted with the syngeneic B16-F1O melanoma (Table 3) . A total of 128 mice of the same age and sex were randomized into 16 groups of eight animals per group. In the afternoon of day -1, 64 animals (eight groups) were surgically traumatized with a full-thickness skin excision followed by abrasion of the normal fascia in the raw skin bed. In the morning of day 0, all traumatized animals plus 64 non-traumatized control animals, were inoculated i.v. with 105 B16-FlO melanoma cells. Treatment with LAN, 500 [.g per injection, in a saline vehicle s.c., b.i.d. for 10 days, was initiated at 1-day intervals beginning on day -1.
As shown in Table 3 , the assay consisted of two animal categories, traumatized and non-traumatized, each consisting of eight groups of animals. Group 1 in each category received no LAN treatment, serving as untreated control animals. LAN treatment was initiated with group 2 in each category in the morning of day -1, i.e. a pretreatment administered approximately 5 h before the surgical wounding of animals in the traumatized category and 24 h before both categories were implanted i.v. with B16-FlO melanoma cells on day 0. Thereafter, LAN treatment of groups in each category was initiated at 1 day intervals. Thus, all groups were seeded i.v. with melanoma cells on the same day and all groups, except for the untreated group 1 controls, received 10 days of LAN treatment. The assay was terminated on day 15 after wounding and the number of macroscopically visible, melanotic lung metastases in the excised lungs of each animal was determined. Onset and duration of the proliferative response of tumours to surgical wounding Sensitivity of the B 16-FIO melanoma to surgical wound-generated stimulatory factors is illustrated by the relative tumour weights on day 15 after implantation ( Figure 1 ). Tumour cells implanted in the surgical wound grew at a rate almost three times faster than that of the same size inoculum implanted in non-traumatized animals. In the following study, B16-F O cells were implanted s.c. in the flank opposite to the surgical wound to determine tumour responses to wound-generated humoral factors. Onset and duration of the proliferative response of s.c. implanted tumours to surgical wounding is summarized in terms of tumour weight and growth rate per day in Table 2 . The same tumour inocula implanted in surgically wounded animals resulted in larger s.c. tumours than in non-wounded animals, when tumour inocula were implanted during the first 2 days after wounding. The greatest difference in proliferative response occurred with tumours implanted on the same day as wounding, e.g. group 1 vs IC (P < 0.05). The rate of tumour growth in traumatized animals implanted on days 3 and 4 after wounding did not differ from their non-traumatized control animals (Figure 2) (Kassabian et al, 1993; Turnbull et al, 1967) . This study was designed to determine (1) the effect of surgical wounding on the seeding of blood-borne metastases; and (2) whether the systemic administration of LAN during the critical tumour-proliferative period 1-2 days after wounding would inhibit seeding of the blood-borne metastases.
The results are summarized in Table 3 Inhibiting the proliferative response of tumours to trauma-associated tumour-stimulatory factors by treating the surgical wound: defining a therapeutic window Our studies had indicated that the surgical trauma-associated, tumour proliferative factor(s) are released soon after wounding, having a duration of approximately 2-3 days. We had also observed that LAN applied topically to the surgical wound appears to inhibit the release of these factors, inducing a therapeutic tumour-inhibitory effect in surgically treated animals (Bogden et al, 1996) . The following studies were designed to confirm the British Journal of Cancer (1997) 75 (7), 1021-1027 findings described above and to test the antisecretagogue activity of LAN further by treating the surgical wound only during the critical first 2-3 days after traumatization. The initial treatment on day 0 was administered within 1 h of wounding. Four human tumours, the MX-1 breast, H-1579 prostate, MIA-PaCa-2 pancreas and DU-145 prostate, were tested in the same experimental design for further confirmation (Table 4) .
All tumours implanted in traumatized, untreated control groups (group 2) showed an enhanced growth when compared with tumours implanted in their respective non-traumatized, untreated controls (group 1). MX-1 breast tumour, showing the lowest proliferative response to trauma, had the tumour-stimulatory effect significantly (P < 0.05) inhibited by a single topical application of LAN. Accelerated growth of the H-1579 prostate tumour was also significantly (P < 0.01) inhibited by a single application of LAN. MIA-PaCa-2 pancreatic tumour required additional treatments of the trauma site on day 1, and the DU-145 prostate tumour required additional treatments on days 1 and 2 to induce a significant (P < 0.05) inhibition of the tumour-stimulatory effect. Importantly, although two tumours required more than a single application of LAN to the wound site, all tumours exhibited a significant nadir of the proliferative response within the first 2-3 days after wounding.
Additional treatment beyond this critical period did not further enhance the tumour-inhibitory effects, suggesting a potential therapeutic window of 1-3 days for the effective application of a somatostatin analogue.
DISCUSSION
That tumour growth-stimulating factors can be generated by simple surgical wounding of normal connective tissues reinforces the role of the surgical wound in the phenomenon of accelerated growth of residual tumours and metastases following surgical extirpation or debulking of a primary tumour mass. The ability of malignant tissues to respond is apparently not an histologically limiting characteristic, as all tumours tested were responsive to surgical wounding. There is also no evidence that wound-generated tumour-stimulating factors are species specific. Both human and animal tumours had an increased rate of growth in surgically traumatized animals. Critical to this phenomenon is the evidence that the tumour-stimulating factors have a humoral component, as evidenced by the proliferative response of tumours distant from the surgical wound.
The relevance of this phenomenon to cancer treatment is emphasized by the fact that tumour proliferation is a risk factor that may be imposed upon every surgical/oncology patient to some degree.
Cytoreductive surgery as an adjuvant treatment for patients whose disease is believed to be too extensive for cure by either drugs or surgery alone is an acceptable and widely used therapeutic modality. Our experimental systems have concentrated on human and animal tumours of the breast and prostate, malignancies in which stimulation of in situ malignant tissue or distant metastases as a result of surgical trauma may be clinically inadvertent. For example, transurethral resections of the prostate in benign prostatic hyperplasia and excisional biopsies (lumpectomies) of the breast are conditions in which surgical trauma may precede histological evidence of the presence or absence of in situ cancer and metastases, and may possibly exacerbate an essentially latent disease.
The primary objective of applying a somatostatin analogue (LAN) as an endocrine antisecretagogue to the wound was to confirm that the tumour-proliferative factors were wound generated.
Tumourproliferative response to surgical wounding 1027 Although delivery of the analogue was transdermal, and thus in all likelihood suboptimal, direct access of the antisecretagogue to the relevant secretory mechanisms in high concentrations may have been facilitated by evading systemic dilution and hepatic passthrough effects. Since the release of tumour growth-stimulatory factors occurs early and is constrained to the 2 or 3 days after wounding, as shown in the paradigm used, the same tumourinhibitory effect might be obtained as a therapeutic endeavour by inserting a short-term, sustained release, somatostatin preparation into the surgical wound, or perhaps, by a simple powdering of wound surfaces with a suitable analogue before wound closure. No attempt has been made to optimize doses or treatment regimens in these studies. Nor has it been within the scope of these studies to identify the various soluble tumour growth factors generated within the wound environment for the healing and repair of surgically damaged normal tissues. The primary objective was to document and define the phenomenon of the surgical wound further as a significant source of tumour-stimulating factors.
The feasibility of inducing a therapeutic tumour-inhibitory effect by inhibiting the phenomenon with a somatostatin analogue augers for a post-operative treatment modality as wound breaking strength assays indicate that somatostatin analogues do not significantly affect wound healing in normal rats (Abribat et al, 1992; Bogden et al, 1996) .
